A phase 1/2 trial of 7MW4911 in advanced solid tumours, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07265622 by Mabwell (Shanghai) Bioscience Co., Ltd., with 200 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-07. Interventions recorded: 7MW4911.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Mabwell (Shanghai) Bioscience and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.